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Aspergillus fumigatus causes varied clinical syndromes ranging from colonization to
deep infections. The mainstay of therapy of Aspergillus diseases is triazoles but
several studies globally highlighted variable prevalence of triazole resistance, which
hampers the management of aspergillosis. We studied the prevalence of resistance
in clinical A. fumigatus isolates during 4 years in a referral Chest Hospital in Delhi,
India and reviewed the scenario in Asia and the Middle East. Aspergillus species
(n = 2117) were screened with selective plates for azole resistance. The isolates
included 45.4% A. flavus, followed by 32.4% A. fumigatus, 15.6% Aspergillus species
and 6.6% A. terreus. Azole resistance was found in only 12 (1.7%) A. fumigatus
isolates. These triazole resistant A. fumigatus (TRAF) isolates were subjected to (a)
calmodulin and β tubulin gene sequencing (b) in vitro antifungal susceptibility testing
against triazoles using CLSI M38-A2 (c) sequencing of cyp51A gene and real-time PCR
assay for detection of mutations and (d) microsatellite typing of the resistant isolates.
TRAF harbored TR34/L98H mutation in 10 (83.3%) isolates with a pan-azole resistant
phenotype. Among the remaining two TRAF isolates, one had G54E and the other had
three non-synonymous point mutations. The majority of patients were diagnosed as
invasive aspergillosis followed by allergic bronchopulmonary aspergillosis and chronic
pulmonary aspergillosis. The Indian TR34/L98H isolates had a unique genotype and
were distinct from the Chinese, Middle East, and European TR34/L98H strains. This
resistance mechanism has been linked to the use of fungicide azoles in agricultural
practices in Europe as it has been mainly reported from azole naïve patients. Reports
published from Asia demonstrate the same environmental resistance mechanism in A.
fumigatus isolates from two highly populated countries in Asia, i.e., China and India and
also from the neighboring Middle East.
Keywords: triazole resistant A. fumigatus, TR34/L98H, G54E, microsatellite typing, India, Asia
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Introduction
Among the Aspergillus species, Aspergillus fumigatus is the lead-
ing etiologic agent of all forms of aspergillosis, which could
be attributed to the ubiquitous presence of its thermo-tolerant
spores that are refractory to adverse environmental condi-
tions (Kwon-Chung and Sugui, 2013). A. fumigatus, in contrast
to Candida albicans, has no reservoir in the immunocompe-
tent population; thus, infections with A. fumigatus are gener-
ally environmentally acquired (Verweij et al., 2009; Chowdhary
et al., 2013b). Furthermore, aspergillosis is associated with
high morbidity and mortality in both immunocompetent and
immunosuppressed populations primarily due to diﬃculties in
early diagnosis or delay in recovery of the immune system
(Kosmidis and Denning, 2015). Triazole antifungals, the com-
petitive inhibitors of cyp51A, are preferred for prophylaxis and
treatment of aspergillosis. However, failure of treatment with
azoles and a steady increase in the occurrence of triazole resis-
tant A. fumigatus (TRAF) isolates from environment as well
as clinical settings has been reported (Denning et al., 1997;
Mellado et al., 2007; Verweij et al., 2007; Rodriguez-Tudela
et al., 2008; Snelders et al., 2008, 2009; Baddley et al., 2009;
Howard et al., 2009; Arendrup et al., 2010; Mortensen et al.,
2010, 2011; van der Linden et al., 2011, 2013; Burgel et al.,
2012; Chowdhary et al., 2012a,b, 2013b, 2014a,b; Alastruey-
Izquierdo et al., 2013; Badali et al., 2013; Bader et al., 2013;
Escribano et al., 2013; Seyedmousavi et al., 2013; Prigitano
et al., 2014; Spiess et al., 2014; Lavergne et al., 2015; Steinmann
et al., 2015). The most common mechanism of triazole resis-
tance has been linked to theTR34/L98H mutation with tandem
repeat in the cyp51A promoter region combined with a sin-
gle amino acid exchange of leucine 98 to histidine (Chowdhary
et al., 2014c). Apparently, this mutated allele has spread through-
out the A. fumigatus population and thus has been reported
worldwide from patients as well as the environment (Mellado
et al., 2007; Verweij et al., 2007; Rodriguez-Tudela et al., 2008;
Snelders et al., 2008, 2009; Baddley et al., 2009; Howard et al.,
2009; Mortensen et al., 2010, 2011; Lockhart et al., 2011; van
der Linden et al., 2011; Burgel et al., 2012; Chowdhary et al.,
2012a,b; Hamprecht et al., 2012; Jeurissen et al., 2012; Morio
et al., 2012; Rath et al., 2012; Alastruey-Izquierdo et al., 2013;
Bader et al., 2013; Escribano et al., 2013; Rocchi et al., 2014;
Kidd et al., 2015; Steinmann et al., 2015). In addition several
point mutations such as G54, G138, or M220 lead to distur-
bances in the docking of azole drugs to cyp51A protein render-
ing azole resistant A. fumigatus phenotype (Diaz-Guerra et al.,
2003; Mann et al., 2003; Mellado et al., 2004; Chen et al., 2005;
Howard et al., 2006, 2009, 2013; Rodriguez-Tudela et al., 2008;
Snelders et al., 2008; Albarrag et al., 2011; van der Linden
et al., 2011). These mutations have been previously reported to
occur de novo due to prolonged exposure of A. fumigatus iso-
lates to azole antifungal drugs in clinical settings (Chen et al.,
2005; Howard et al., 2009; Escribano et al., 2012). However,
a recent study reports presence of A. fumigatus carrying G54
point mutation in the environment of Tanzania, Romania, and
India suggesting that environment may predominately be the
cause in acquisition of azole resistant isolates (Sharma et al.,
2015). Also, non-cyp51A mediated mutations have been increas-
ingly recognized in the development of azole resistance and
are mainly reported from Manchester, UK (Bueid et al., 2010).
We conducted a prospective study for the assessment of preva-
lence of TRAF and the underlying cyp51A mutations in clinical
isolates of Aspergillus species collected during a 4-year (2011–
2014) period in a referral Chest Hospital in Delhi, India and
reviewed the reports on TRAF isolates from environmental
and clinical sources from Asia and the neighboring Middle
East.
Materials and Methods
Fungal Isolates and Their Phenotypic
Characterization
During 2011–2014 a total of 8222 clinical samples were
processed for fungal culture and microscopy collected from
patients of our hospital and three neighboring referral hospi-
tals included in Table 1. The clinical specimens included spu-
tum, endotracheal aspirates, bronchial aspirates, bronchoalve-
olar lavages (BAL), bronchial tissues, ﬁne needle aspiration
biopsies, lung biopsies, nasal polyps, bone marrow aspira-
tions, pleural ﬂuid, bronchial plugs, and cerebrospinal ﬂuid.
The study was approved by the Institute’s Ethics Committee.
All Aspergillus species cultured from the specimens were pre-
liminarily identiﬁed based on colony color and morphol-
ogy of the isolates on Czapek dox agar plates incubated
at 28◦C for 7 days. In order to investigate azole resis-
tance in all of the Aspergillus species, they were screened
on itraconazole (ITC, 4 μg/ml) and voriconazole (VRC,
1 μg/ml) supplemented Sabouraud dextrose agar (SDA) plates.
Aspergillus isolates that exhibited growth on either of the
antifungal plate were conﬁrmed as Aspergillus species by
ampliﬁcation and sequencing of β-tubulin and calmodulin
genes.
Antifungal Susceptibility Testing (AFST)
All resistant A. fumigatus were subjected to AFST against four
standard medical triazoles, amphotericin B (AMB), echinocan-
dins, and 10 commonly used azole fungicides using CLSIM38-A2
broth microdilution Clinical and Laboratory Standards Institute
[CLSI] (2008). The drugs tested included ITC (Lee Pharma,
Hyderabad, India, and Janssen Research Foundation, Beerse,
Belgium), VRC (Pﬁzer Central Research, Sandwich, Kent, UK),
isavuconazole (ISA, Basilea Pharmaceutica International AG,
Basel, Switzerland), posaconazole (POS, Merck, Whitehouse
Station, NJ, USA), AMB (Sigma–Aldrich, Germany), caspo-
fungin (CAS, Merck), micafungin (MFG, Astellas Toyama
Co. Ltd., Japan), and anidulafungin (AFG, Pﬁzer). The tested
azole fungicides were bromuconazole, cyproconazole, difeno-
conazole, epoxiconazole, penconazole, tebuconazole, triadime-
fon, metconazole, hexaconazole (Rallis India, Mumbai, India),
and tricyclazole (Cheminova India, Mumbai, India). The
AFST results were analyzed by using epidemiological cutoﬀ
values (ECVs) proposed by Espinel-Ingroﬀ et al. (2011a,b,
2013) ITC, 1 μg/ml; VRC, 1 μg/ml; POS, 0.5 μg/ml; ISA,
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1 μg/ml, AMB, 4 μg/ml, and CAS, 0.25 μg/ml (Pfaller et al.,
2011).
Mutation Analysis
To gain insight into the mechanisms responsible for azole resis-
tance in A. fumigatus, isolates were subjected to ampliﬁca-
tion and sequencing of cyp51A gene along with the promoter
region (Sharma et al., 2015). The ampliﬁed product was puri-
ﬁed followed by sequencing on an ABI 3130XL genetic analyzer
(Applied Biosystems, Foster City, CA, USA) using the BigDye
terminator kit (v3.1, RR-100; Applied Biosystems; Chowdhary
et al., 2013a). DNA sequences were analyzed with Sequencing
Analysis software version 5.3.1 (Applied Biosystems). Consensus
sequences were made using BioEdit software (version 7.0.5.3;
Hall, 1999). The sequences of the resistant A. fumigatus strains
were compared with the wild type susceptible reference A. fumi-
gatus strain (Af293). The mutations in the resistant strains were
further conﬁrmed by mixed format real time PCR analysis as
described previously (Klaassen et al., 2010).
Microsatellite Typing
The genotypic relationship of the Indian resistant A. fumigatus
isolates with the isolates from Asia, Middle East, and Europe
harboring various mutations in cyp51A gene was determined by
microsatellite typing using a panel of nine short tandem repeats
(STR) as described previously (de Valk et al., 2005). The ampli-
ﬁcation of three di-, tri-, or tetranucleotide repeat markers was
carried out using three multiplex PCRs, namely, M2, M3, and
M4, respectively, (de Valk et al., 2005). Repeat numbers in each
marker was assigned using A. fumigatus Af293 as reference. The
STR data was imported to BioNumerics v5.1 software (Applied
Maths, Sint-Martens-Latem, Belgium) for phylogenetic analy-
sis. The dendrogram based on unweighted pair-group method
with arithmetic mean (UPGMA) clustering using the Pearson
correlation coeﬃcient was generated. A total of 49 A. fumiga-
tus isolates from Asia, Middle East, Europe, and Australia were
included as controls to evaluate the genetic diﬀerences with the
A. fumigatus isolates from India. The isolates from outside India
were from following countries: China (clinical resistant, n = 8),
Iran (environmental resistant, n = 5; environmental suscepti-
ble, n = 4), Kuwait (clinical resistant, n = 2; clinical susceptible,
n = 2; environmental resistant, n = 8; environmental suscepti-
ble, n = 2), France (clinical resistant, n = 1), Germany (clinical
resistant, n = 7; clinical susceptible, n = 1), the Netherlands
(clinical resistant, n = 2; environmental resistant, n = 3), and
Australia (clinical resistant, n = 2; clinical susceptible, n = 2).
Also, Indian isolates (environmental resistant n = 3; environ-
mental susceptible n = 6 and clinical susceptible n = 3) collected
during the previous study on resistant A. fumigatus were included
for comparison with the present clinical TRAF isolates from India
(Chowdhary et al., 2012b).
Results
Overall, during a 4-year survey period, 25.7% of clinical sam-
ples harbored Aspergillus species (n = 2117). Out of these 2117
isolates, 45.4% (n = 963) were A. flavus, followed by 32.4%
(n = 685) A. fumigatus, 15.6% (n = 329) Aspergillus species and
6.6% (n = 140) A. terreus (Kathuria et al., 2015). Barring 12 iso-
lates of A. fumigatus none of the other Aspergillus species grew
on SDA plates supplemented with ITC and/or VRC. Of these,
11 A. fumigatus grew on both ITC and VRC supplemented SDA
plates while a solitary isolate grew only on ITC plate. All the 12
resistant isolates were identiﬁed as A. fumigatus sensu stricto by
β-tubulin and calmodulin genes sequencing.
Of the 12 resistant A. fumigatus, 11 showed a pan-azole
resistant phenotype exhibiting high MIC of all the triazoles,
namely, ITC [geometric mean (GM) MIC, 16 μg/ml], VRC
(GM MIC, 8 μg/ml), ISA (GM MIC, 6.34 μg/ml), and POS
(GM MIC, 2.82 μg/ml). In contrast, a solitary A. fumigatus iso-
late exhibited high MIC of only ITC (>16 μg/ml) and POS
(1 μg/ml; Table 1). However, AMB (GM MIC, 0.4 μg/ml) and
three echinocandins, namely, CAS, MFG, and AFG were active
against all the resistant A. fumigatus isolates with GM MICs of
0.13μg/ml, 0.017μg/ml, and 0.02μg/ml, respectively. Further all
TRAF uniformly revealed cross-resistance to all the azole fungi-
cides (MICs,>32 μg/ml) tested excepting metconazole (MICs,
3.80 μg/ml).
Overall, 1.75% (12/685) of the clinical A. fumigatus iso-
lates were resistant. The major resistance mechanism observed
among the eleven pan-azole resistant phenotype was TR34/L98H
mutation (n = 10) and a solitary isolate exhibited three non-
synonymous point mutations, namely, F46Y, D255E, andM172V.
Another single point mutation, G54E, was observed in a solitary
isolate that had high MICs to both ITC and POS.
The STR typing data revealed a single microsatellite complex
(MC) among all the TR34/L98H genotypes whereas solitary iso-
late each of G54E and non-synonymous mutant of A. fumigatus
represented two distinct genotypes (Figure 1). The TR34/L98H
MC was homogenous and shared all the nine loci except one iso-
late that diﬀered at two loci (4A and 4C). Further to determine the
genetic relatedness among the present Indian TR34/L98H clinical
isolates (n = 10) comparison with Indian TR34/L98H environ-
mental isolates (n = 3) collected from the previous study was
done (Chowdhary et al., 2012b). Both the environmental and
clinical A. fumigatus isolates had an identical STR pattern. The
genotypes of all Indian TR34/L98H isolates were distinct from
the TR34/L98H strains of Chinese, Kuwait, Iran, and European
isolates (Lockhart et al., 2011; Badali et al., 2013; Ahmad et al.,
2014, 2015; Steinmann et al., 2015). However, environmental
A. fumigatus isolates from Kuwait (n = 4) and Iran (n = 5)
were more closely related with Indian TRAF isolates with sim-
ilarity observed at 5–6 of the nine loci studied. Although the
Chinese clinical TRAF isolates (n = 8) also formed a separate
cluster but unlike Indian isolates they were markedly heteroge-
neous exhibiting variable STR patterns. The STR typing data of
the clinical Kuwait TRAF isolates (n = 6) revealed homogeneity
among them, however, when compared to Indian TRAF clini-
cal isolates they showed diﬀerences at 6–7 loci (Ahmad et al.,
2015).
The detailed clinical record of all patients whose clinical sam-
ples yielded TRAF was retrieved from the database. The majority
of patients were diagnosed as invasive aspergillosis (IA, n = 5)
Frontiers in Microbiology | www.frontiersin.org 4 May 2015 | Volume 6 | Article 428
Chowdhary et al. Triazole resistant clinical A. fumigatus, India
FIGURE 1 | Genotypicrelationship of Indian Aspergillus fumigatus
isolates (clinical resistant, n = 14; clinical susceptible, n = 3;
environmental resistant, n = 3; environmental susceptible, n = 6) with
isolates from Asia including China (clinical resistant, n = 8), Middle East
including Iran (environmental resistant, n = 5; environmental
susceptible, n = 4), and Kuwait (clinical resistant, n = 2; clinical
susceptible, n = 2; environmental resistant, n = 8; environmental
susceptible, n = 2), and Europe including France (clinical resistant,
n = 1), Germany (clinical resistant, n = 7; clinical susceptible, n = 1), the
Netherlands (clinical resistant, n = 2; environmental susceptible, n = 3),
and Australia (clinical resistant, n = 2; clinical susceptible, n = 2). The
dendrogram is based on a categorical analysis of nine microsatellite markers in
combination with Unweighted Pair Group Method with arithmetic mean
clustering. The scale bar indicates the percentage identity. The isolates VPCI
343/P/11/1, VPCI 343/P/11/2, and VPCI 245/P/12-1, VPCI 245/P/12-2 were
serial isolates from two individual patients, respectively.
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followed by allergic bronchopulmonary aspergillosis (ABPA,
n = 4) and chronic pulmonary aspergillosis (CPA, n = 3). The
most common underlying condition among the IA patients was
chronic obstructive pulmonary disease (COPD) in three patients
and myelodysplastic syndrome and pulmonary adenocarcinoma
in the remaining two patients, respectively. IA was deﬁned as
probable or proven according to the criteria of the European
Organization for Research and Treatment of Cancer/Mycoses
Study Group (Ascioglu et al., 2002; De Pauw et al., 2008). All
cases of IA in the present studywere proven cases and FNAB/lung
biopsy or resected sinus tissue was positive for fungus and yielded
A. fumigatus in culture. IPA (n = 4) was the most common mani-
festation and a solitary case had invasive rhino-cerebral sinusitis.
All COPD patients who ﬁnally developed IA during the course
of 5–10 years of illness had been admitted to the medical units
or ICU repeatedly (4–9 episodes per year) for respiratory symp-
toms with severe airﬂow obstruction. All these patients were on
systemic and inhaled steroids for a long period ranging from 10
to 12 years. Associated co-morbidities like diabetes mellitus and
tuberculosis were observed in two of the three COPD patients.
Allergic aspergillosis manifesting as ABPA was diagnosed in four
patients by a combination of clinical, mycoserologic, and radio-
logical features (Agarwal et al., 2013). None of the ABPA patients
diagnosed in the present study were on azoles when their culture
grew TRAF. The third clinical entity was CPA, which was diag-
nosed by chronic duration of clinical symptoms (>3 months),
progressive pulmonary lesions with or without cavitation, pre-
cipitating antibodies to A. fumigatus in serum, and mycological
evidence of fungal presence. Further, none of the patients har-
boring identical TR34/L98H genotype (n = 10) admitted to the
Chest hospital (n = 8) in the present study had an overlapping
time frame during their admission. Also, two patients harbor-
ing the same genotype were from two diﬀerent hospitals in Delhi
(Table 1).
Overall, the mortality was highest in IA (four of ﬁve patients)
and CPA (two of three patients) and a solitary case of ABPA
also had a fatal outcome. Among IA patients, VRC (6 mg/kg
intravenous 12 hourly followed by 4 mg/kg and switched to oral
200 mg twice a day when clinically stable) was administered
in three patients and two were started on AmB deoxycholate
(1 mg/kg/day). All CPA patients were given VRC for 7–10 days
before the antifungal susceptibility results were conveyed. The
two CPA patients had severe lung involvement and the disease
was fatal in both of them within 1 week. However, in one case
therapy was switched to amphotericin B for one month fol-
lowed by repeat BAL culture that yielded negative results for
Aspergillus and the patient was discharged on oral VRC on fol-
low up. However, patient failed to report for the follow up
visits. The patients with ABPA in the present study were man-
aged symptomatically and systemic steroids were the mainstay of
therapy.
Discussion
In the present study, we examined azole susceptibility and resis-
tant mechanisms among A. fumigatus isolates from patients
with bronchopulmonary aspergillosis in a referral Chest Institute,
which caters to a vast population of Delhi and adjoining states of
Uttar Pradesh, Haryana and also to far remote regions of India.
The rate of azole resistance in A. fumigatus isolates in our study
was 1.75% (12/685) during a 4-year period, which is remarkably
low compared to the high prevalence in Europe including UK
(6.6–27.8%), the Netherlands (3.1–4.6%), and Germany (3.2%;
Snelders et al., 2008; Howard et al., 2009; Bueid et al., 2010; van
der Linden et al., 2011; Bader et al., 2013). In contrast in Spain,
a lower prevalence rate (2.5%) of azole resistance in A. fumiga-
tus complex has been reported suggesting that azole resistance
has not yet uniformly spread in Europe (Escribano et al., 2013).
TR34/L98H was the predominant resistance mechanism in 83.3%
of the Indian TRAF isolates followed by G54E (n = 1) and a
non-synonymous mutation (n = 1).
Short tandem repeats typing of the TRAF isolates demon-
strated a single cluster, with a homogenous population. It is
also worth mentioning here that the patients’ positive for TRAF
isolates in the present study were both from Delhi, and other
states namely West Bengal, Haryana, and Uttar Pradesh. These
states previously have been found to harbor A. fumigatus isolates
carrying TR34/L98H in soil samples (Chowdhary et al., 2012b).
Notably the genotype detected in clinical isolates in this study was
identical to the TR34/L98H genotype reported earlier from envi-
ronmental samples from India and shared the identical nine loci,
suggesting environmental origin of this major resistance mech-
anism (Chowdhary et al., 2012b). This is the ﬁrst study outside
the Netherlands revealing the possibility of acquisition of clinical
isolates linked with the environment. However, in contrast to the
heterogeneity observed in environmental and clinical isolates in
the Netherlands (Klaassen et al., 2012), the Indian TRAF in the
present study had a homogenous population which was recently
also conﬁrmed with whole genome sequencing (Abdolrasoulia
et al., 2015).
Table 2 summarizes the reports of TRAF isolation harbor-
ing mutations in the cyp51A gene from clinical and environ-
mental sources in Asia and the neighboring Middle East. The
initial reports describing azole resistance in clinical A. fumiga-
tus isolates originated from Europe in the late 1990s followed by
systematical investigations in several European countries which,
reported prevalence, mechanism, and genomic aspects of TRAF
(Mellado et al., 2007; Verweij et al., 2007; Rodriguez-Tudela et al.,
2008; Howard et al., 2009; Mortensen et al., 2010; Burgel et al.,
2012; Morio et al., 2012; Bader et al., 2013; Astvad et al., 2014;
Fischer et al., 2014; Spiess et al., 2014; van der Linden et al.,
2015). However, the ﬁrst comprehensive report on the occur-
rence of TRAF isolates in Asia originated from China during
2008–2009 from the ARTEMIS global sentinel surveillance pro-
gram demonstrating TR34/L98H resistance mechanism in 27.5%
(8/29) A. fumigatus isolates (Lockhart et al., 2011; Table 2).
In contrast, more recently few studies from Japan, described
TRAF in clinical isolates but interestingly none of them exhib-
ited TR34/L98H resistance mechanism, instead several SNPs and
novel mutations, F332K and P216L were reported (Asano et al.,
2011; Hagiwara et al., 2014). The single center study from Japan
reported 5.2% (1/19) TRAF isolates harboring only G54E/R/W
and I266N mutation (Tashiro et al., 2012a,b). Notably, a recent
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TABLE 2 | Distribution of TRAF in clinical and environmental samples in Asia and Middle East harboring mutations in the Cyp51A gene.
Country Resistance
mechanism
Source Resistance rate (No. of resistant
A. fumigatus / No. of A. fumigatus tested)
Reference
China M220I, G54R Clinical 4/6 (66.6%)a Chen et al. (2005); Xu et al. (2010)
TR34/L98H Clinical 8/29 (27.5%) Lockhart et al. (2011)
SNPb Environmental, Poultry 11c/175 Wang et al. (2014)
India TR34/L98H Clinical 2/103 (1.9%) Chowdhary et al. (2012a)
TR34/L98H Environmental 44/630 (7%) Chowdhary et al. (2012b)
TR34/L98H &
TR46/Y121F/T289A
Environmental 8/126 (6.3%)
6/126 (4.8%)
Chowdhary et al. (2014a)
TR34/L98H &
G54E
Environmental 4/5 (80%)
1/5 (20%)
Sharma et al. (2015)
Iran TR34/L98H Clinical 4/124 (3.2%) Seyedmousavi et al. (2013)
TR34/L98H Environmental 5/41 (12.1%) Badali et al. (2013)
Japan F332K Clinical 1/19 (5.2%) Asano et al. (2011)
G54E/R/W and
I266N
Clinical 12/196 (6.1%) Tashiro et al. (2012a; 2012b)
P216L Clinical 1/8 (12.5%) Hagiwara et al. (2014)
Kuwait TR34/L98H Environmental 8/115 (7%) Ahmad et al. (2014)
TR34/L98H Environmental 1/50 (2%) Ahmad et al. (2015)
TR34/L98H Clinical 2/16 (12.5%) Ahmad et al. (2015)
Taiwan Not mentionedd Clinical 2/40 (5%) Hsueh et al. (2005)
aserial isolates from a patient suffering from lung aspergilloma; bSNP, single nucleotide polymorphisms such asF46Y, M172V, N248T, N248K, D255E, and E427K also
present in susceptible A. fumigatus strains were detected; ctotal no. of A. fumigatus obtained from French and Chinese avian farms; dThe mutation in cyp51A gene was
not investigated.
study on environmental sampling of air from a pumpkin farm
sprayed with azole fungicides, at Nihon University, Japan was
carried out by using an outdated and less eﬃcacious settle plate
method and reported no azole resistance in 50 A. fumigatus iso-
lates (Kano et al., 2015). The lack of isolation of TRAF could be
attributed to not adopting a highly eﬃcacious sampling method
such as using an air sampler and to the low number of isolates
tested for resistance resulting in false rates of TRAF prevalence
in the environment. The possibility of missing resistance was
recently also highlighted in the SCARE study (van der Linden
et al., 2015). Further, planned studies with wider coverage areas
and diﬀerent sources such as soil samples, air, wooden debris
etc., should be undertaken for ﬁnding out the true prevalence
of TRAF isolates. In India, a comprehensive wider environmen-
tal survey covering north, south, and eastern India analyzed 486
environmental samples comprising soil from ﬂowerbeds of nurs-
eries, surrounding parks of hospitals, cotton trees, tea gardens,
paddy ﬁelds, soil containing bird excreta, and decayed wood
of tree trunks revealed 7% TRAF isolates in the environment
carrying TR34/L98H mutation (Chowdhary et al., 2012b). Also,
a recently described VRC resistant TR46/Y121F/T289A mecha-
nism was observed in environmental A. fumigatus isolates from
agricultural ﬁelds in India (Chowdhary et al., 2014a). Barring
the solitary environmental report on TR46/Y121F/T289A mecha-
nism from India none of the clinical or environmental samples
from Asia has yet documented the occurrence of A. fumigatus
isolates carrying this mechanism so far. However, considering the
presence of this new resistant mechanism in the environment of
India it may be anticipated that in future it may spread to the
neighboring Asian countries. In addition to the above-discussed
reports on triazole resistance in Asia, the neighboring Middle
East countries, Iran, and Kuwait had reported 12.2 and 7% TRAF
carrying TR34/L98H resistance in the environment, respectively,
(Badali et al., 2013; Ahmad et al., 2014). A similar range of
resistance prevalence of 3.2 and 12.5% TR34/L98H A. fumigatus
isolates was observed in clinical samples from CPA and ABPA
patients from Iran and Kuwait, respectively, (Seyedmousavi et al.,
2013; Ahmad et al., 2015). Based on the fact that the Indian
TRAF isolates exhibited a distinct cluster away from the Chinese
TR34/L98H isolates, it may be suggested that resistance among
the A. fumigatus strains across Asia has evolved from separate
strains and not from a common resistant ancestor, which may
have spread worldwide.
It is also pertinent to mention that the high rates of tria-
zole resistance in Europe as compared to Asia could be due
to environmental factors or more so by frequent use of azoles
in clinical settings and in the environment. Azole fungicides
are extensively used in agriculture for crop protection to con-
trol mildews and rusts of grains, fruits, vegetables, and also
for preservation of materials like wood etc. Geographically,
Europe is the dominant market where fungicide usage is sig-
niﬁcantly high in production of fruits and vegetables along
with wheat and vineyard (Stensvold et al., 2012). Thus, the
reports of high resistance rates in environmental A. fumigatus
isolates from the Netherlands, Belgium, UK, and Germany can
be attributed to higher fungicide usage. Similarly, the absence
or very low prevalence of triazole resistance in A. fumigatus
in the USA could possibly be due to the low usage of fungi-
cides in the USA as compared to Europe1. Notably, triazole
resistance was screened among 1026 A. fumigatus isolates from
1http://ec.europa.eu/food/fs/sc/ssc/out278en.pdf
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22 states of USA and none had TR34/L98H mutation (Pham
et al., 2014). In India, the crop protection chemicals account for
∼2% of the total chemicals market and currently India is the
second largest manufacturer of pesticides in Asia, second only
to Japan2. Among diﬀerent classes of pesticides used in India
the percent share of insecticides (60%) is highest followed by
fungicides (19%), herbicides (16%), biopesticides (3%), and oth-
ers (3%). Per capita consumption of crop protection products in
India is 0.6 kg/ha compared to 16 kg/ha in Taiwan, 13 kg/ha in
China, and 12 kg/ha in Japan2. Finally, the environmental resis-
tance mechanism in A. fumigatus isolates have been reported
from two highly populated countries in Asia, i.e., China and
India. Further, the environment of agricultural ﬁelds in India has
been harboring variable cyp51A mediated resistant patterns in
A. fumigatus isolates, which are continuously exposed to agri-
cultural azole fungicides. It is emphasized that in depth analysis
2 http://www.ﬁcci.com/spdocument/20292/petro1.pdf
of azole resistance in A. fumigatus isolates in both clin-
ical laboratories and environmental settings is required to
prevent its spread and emergence in neighboring Asian
countries.
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